

Scope of Work for Consultant - Clinical Pharmacist

1. Background:

National List of Essential Medicines is one of the key instruments in balanced healthcare delivery system of a country which includes accessible, affordable, quality medicine at all the primary, secondary, tertiary levels of healthcare. In line with WHO Model List of Essential Medicines, Nepal has been implementing a National List of Essential Medicines (NLEM) since 1986 AD. NLEM is the basis for the selection of medicines for government health facilities in Nepal. NLEM was revised in 1992, 1997, 2002, 2011, 2016 and 2021 AD. The revision exercise identifies cost effective medicines for priority conditions, together with reasons for their inclusion, linked to evidence based clinical guidelines and giving special emphasis on public health aspects and considerations of value for money. Considering the needs to meet the common contemporary and priority health needs of the population of the country and giving special emphasis of public health aspects with due regard to relevant disease prevalence and changing health care needs, the revision of NLEM in a timely manner is needed. Revision of the NLEM 2025 is suggested to align with Basic Health Care Service package and different national vertical programs.

2. Objective:

The consultant – clinical pharmacist will ensure the clinical relevance, safety, and practicality of the medicines listed in the revised NEML, focusing on patient-centered care and public health priorities.

3. Key Responsibilities:

The consultant will:

- Review and validate the clinical appropriateness of the existing and proposed medicines.
- Engage with clinicians, national programs, and stakeholders to gather practical insights.
- Align proposed changes with the Basic Health Care Service package and national clinical guidelines.
- Ensure AWARE categorization of antibiotics is clinically appropriate.
- Participate in expert review committee meetings and workshops to provide clinical insights.
- Assist in drafting the revised NEML from a clinical perspective.

4. Duration and Timeline

The consultancy will span 30 working days, commencing in May and concluding by July 15, 2025.

5. Reporting Requirements:

- Submission of clinical review report highlighting evaluations and recommendations.
- Detailed input on proposed medicine additions, deletions, and modifications.
- Summary report of workshop and stakeholder consultation attended.
- Compile and prepare the final draft of the revised NEML.

6. Payment Terms

Payments will be made in two installments, tied to the successful completion and approval of specific deliverables as agreed upon in the contract.

- Payment 1 (50%) - Summary report of workshop and stakeholder consultation attended.
- Payment 2 (50%) - Final draft report of the revised NEML.

7. Qualifications:

- Degree in pharmacy with specialization in clinical pharmacy.
- At least 3-5 years of relevant experience, particularly in developing or revising medicines formularies, clinical protocols, and treatment guidelines.

8. Performance Standards

All deliverables must adhere to Helen Keller International's quality standards, with timely submissions and responsiveness to feedback.

9. Confidentiality & Ethics

The consultant must comply with Helen Keller International's confidentiality, ethical, and safeguarding policies throughout the consultancy engagement.